Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

“The statute and our guidance [are] very clear that when a drug is selected for negotiation, all dosage forms and strengths with the same active ingredients are included, even if they are sold under ...

At the J.P. Morgan Health Care conference this week in San Francisco, drugmakers had their sights set on the next generation of GLP-1 medications, alternatives, and a growing list of indications ...

The results were also consistent across varying subgroups, including by age, type of GLP-1 RA, and cumulative dose of GLP-1 RAs. Further analysis showed no increased risk for thyroid cancer based ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released ...

According to KFF, just 18% of companies with 200 or more employees cover GLP-1 drugs, a class of medications that reduce blood sugar levels and regulate appetite. Given that these drugs cost $700 to ...